bluebird bio Inc (NASDAQ:BLUE)
| 83.12 Delayed Data As of Jan 27 |  -4.14 / -4.74%Today’s Change | 71.42 Today|||52-Week Range 163.43 | -5.28% Year-to-Date |
Latest BLUE News | Press Releases
| FDA Puts GlaxoSmithKline's Blood Cancer Drug In the Fast Lane Jan 21 / MotleyFool.com - Paid Partner Content | 2 Biotech Stocks to Watch In 2020 Jan 17 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 87.26 |
| Today’s open | 85.51 |
| Day’s range | 83.03 - 85.87 |
| Volume | 1,412,381 |
| Average volume (3 months) | 1,133,280 |
| Market cap | $4.8B |
Data as of 4:00pm ET, 01/27/2020
Growth & Valuation
| Earnings growth (last year) | -38.51% |
| Earnings growth (this year) | -31.55% |
| Earnings growth (next 5 years) | -64.66% |
| Revenue growth (last year) | +54.06% |
| P/E ratio | NM |
| Price/Sales | 94.57 |
| Price/Book | 2.53 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ARWRArrowhead Pharmaceut... | -0.60 | -1.34% |
| ---- | ||
| MORMorphoSys AG | -0.64 | -1.95% |
| IMMUImmunomedics Inc | -0.22 | -1.20% |
Data as of 4:00pm ET, 01/27/2020
Financials
| Next reporting date | March 2, 2020 |
| EPS forecast (this quarter) | -$3.77 |
| Annual revenue (last year) | $54.6M |
| Annual profit (last year) | -$555.6M |
| Net profit margin | -1,018.02% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
